Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Emtricitabine/Tenofovir disoproxil Krka

Emtricitabine/Tenofovir disoproxil Krka 200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17–18

HOS-136606 · Präparat HOS-097888

17 Sofosbuvir/Velpatasvir/ Sofosbuvir: Increased plasma concentrations of Voxilaprevir (400 mg/100 mg/ AUC: ↔ tenofovir resulting from co 100 mg+100 mg q.d.)3 + Darunavir Cmax: ↓ 30% administration of tenofovir disoproxil, (800 mg q.d.) + Ritonavir (100 mg Cmin: N/A sofosbuvir/velpatasvir/voxilaprevir and q.d.) + Emtricitabine/Tenofovir darunavir/ritonavir may increase disoproxil (200 mg/245 mg q.d.) GS-3310072: adverse reactions related to tenofovir AUC: ↔ disoproxil, including renal disorders. Cmax:↔ The safety of tenofovir disoproxil when Cmin: N/A used with sofosbuvir/velpatasvir/voxilaprevir and Velpatasvir: a pharmacokinetic enhancer (e.g. AUC: ↔ ritonavir or cobicistat) has not been Cmax: ↔ established. Cmin: ↔ The combination should be used with Voxilaprevir: caution with frequent renal monitoring AUC: ↑ 143% (see section 4.4). Cmax:↑ 72% Cmin: ↑ 300%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521)